Primary Bile Acid Biosynthesis Analysis Service

v-innovate Technologies is a pioneer in metabolism service and provides reliable, professional and cost-effective primary bile acid biosynthesis analysis service in animal. We leverage our ample experience, professional expertise, and advanced technologies to accelerate your scientific purposes of primary bile acid biosynthesis analysis in animal.

Overview

Bile acids formed by synthesis in the liver are termed primary bile acids. In the liver, synthesis of bile acids and bile salts is initiated with the conversion of cholesterol esters to cholesterol. The primary bile acids are conjugated with taurine or the amino acid glycine before secretion via bile into the intestine, where they function as detergents to solubilize dietary fats. Conjugation increases water solubility, preventing passive re-absorption once secreted into the small intestine. As a consequence, the concentration of bile acids in the small intestine can keep high enough to form micelles and solubilize lipids. Therefore, primary bile acid biosynthesis is a critical component of lipid metabolism. The dysfunction of primary bile acid biosynthesis could lead to a variety of human diseases such as Perrault syndrome and cerebrotendinous xanthomatosis. In v-innovate Technologies, we provide reliable, rapid and cost-effective fatty acid synthesis related service to speed up your research aims ranging from diseases diagnosis to gaining new insights in disease mechanism or treatment.

The Main Applications of Primary Bile Acid Biosynthesis Service

Identifying novel biomarkers of diseases

Improving diagnose diseases

Accelerating development of novel drugs

Gaining new mechanism of diseases

Advantages of Our Primary Bile Acid Biosynthesis Service

Constantly optimized protocol and analytical software

Professional experiment design

Quick turnaround time

High accuracy, specificity, and sensitivity

Service Workflow

v-innovate Technologies provides primary bile acid biosynthesis analysis service in a reliable and effective manner, based on our cutting-edge high-performance liquid chromatography (HPLC) platforms. The experimental procedures contain four main procedures: sample collection, metabolites extraction, HPLC data analysis and bioinformatics analysis (Figure 1). Our service will be tailored to specific samples and needs for optimal results.

Figure 1. The overall workflow of primary bile acid biosynthesis.

List of Detectable Primary Bile Acid Biosynthesis Related Metabolites at v-innovate Technologies

24-Hydroxycholesterol	(24S)-Cholest-5-ene-3β,7α,24-triol	7α,24-Dihydroxy-4-cholesten-3-one	Cholest-5-ene-3β,7α,25-triol
25-Hydroxycholesterol	7α-Hydroxy-3-oxo-4-cholestenoate	7α,25-Dihydroxy-4-cholesten-3-one	7α,27-Dihydroxycholesterol
26-Hydroxycholesterol	7α,26-Dihydroxy-4-cholesten-3-one	3β,7α -Dihydroxy-5-cholestenoate	3β-Hydroxy-5-cholestenoate

Sample Requirements

We can analyze a wide range of biological materials including but not limited to cells and solid tissues from humans and animals, such as mice, rats, rabbits. If you need transport your samples to us, please follow the following requirements for different types of sample:

• Blood/plasma: 500ul/sample
• Urine: 1ml/sample
• Tissue: 200mg/sample
• Cells: 1x10⁷/sample
• Feces: 500mg/sample
• Shipment condition: dry ice

Report Delivery

• Experimental protocols
• Instrumental factors of HPLC
• The raw data files of HPLC and the summary of HPLC data quality
• Bioinformatics analysis report

Based on advanced HPLC platforms for the determination of primary bile acid biosynthesis, professional bioinformatic analysis software and experienced technicians and scientists, v-innovate Technologies provides customer-tailored primary bile acid biosynthesis analysis service with rapid experimental procedures and easy to read report, to accelerate your scientific research.

References

1. Pierce Sarah B, Chisholm Karen M, Lynch Eric D, et al. Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome. Proc Natl Acad Sci U S A. 2011.108:6543-6548.
2. Moghadasian Mohammed H. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med. 2004.27:42-50.